EP1017366A4 - Solid coprecipitates for enhanced bioavailability of lipophilic substances - Google Patents

Solid coprecipitates for enhanced bioavailability of lipophilic substances

Info

Publication number
EP1017366A4
EP1017366A4 EP97940639A EP97940639A EP1017366A4 EP 1017366 A4 EP1017366 A4 EP 1017366A4 EP 97940639 A EP97940639 A EP 97940639A EP 97940639 A EP97940639 A EP 97940639A EP 1017366 A4 EP1017366 A4 EP 1017366A4
Authority
EP
European Patent Office
Prior art keywords
coprecipitates
solid
lipophilic substances
enhanced bioavailability
bioavailability
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97940639A
Other languages
German (de)
French (fr)
Other versions
EP1017366A1 (en
Inventor
Shimon Amselem
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmos Corp
Original Assignee
Pharmos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL11917696A external-priority patent/IL119176A/en
Priority claimed from US08/833,076 external-priority patent/US5891469A/en
Application filed by Pharmos Corp filed Critical Pharmos Corp
Publication of EP1017366A1 publication Critical patent/EP1017366A1/en
Publication of EP1017366A4 publication Critical patent/EP1017366A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
EP97940639A 1996-09-01 1997-08-27 Solid coprecipitates for enhanced bioavailability of lipophilic substances Withdrawn EP1017366A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IL11917696 1996-09-01
IL11917696A IL119176A (en) 1996-09-01 1996-09-01 Soluble coprecipitates for enhanced oral bioavailability of lipophilic substances
US833076 1997-04-02
US08/833,076 US5891469A (en) 1997-04-02 1997-04-02 Solid Coprecipitates for enhanced bioavailability of lipophilic substances
PCT/US1997/015072 WO1998008490A1 (en) 1996-09-01 1997-08-27 Solid coprecipitates for enhanced bioavailability of lipophilic substances

Publications (2)

Publication Number Publication Date
EP1017366A1 EP1017366A1 (en) 2000-07-12
EP1017366A4 true EP1017366A4 (en) 2006-03-22

Family

ID=26323300

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97940639A Withdrawn EP1017366A4 (en) 1996-09-01 1997-08-27 Solid coprecipitates for enhanced bioavailability of lipophilic substances

Country Status (5)

Country Link
EP (1) EP1017366A4 (en)
JP (1) JP2001523221A (en)
AU (1) AU730216B2 (en)
CA (1) CA2264718C (en)
WO (1) WO1998008490A1 (en)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
US5891845A (en) * 1997-11-21 1999-04-06 Fuisz Technologies Ltd. Drug delivery systems utilizing liquid crystal structures
IT1298731B1 (en) * 1998-03-13 2000-02-02 Recordati Chem Pharm PHARMACEUTICAL COMPOSITIONS CONTAINING COMPLEX INCLUSION WITH MELATONIN
US6241969B1 (en) * 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
US6200550B1 (en) * 1998-12-11 2001-03-13 Q-Pharma, Inc. Oral care compositions comprising coenzyme Q10
US6045826A (en) 1999-04-02 2000-04-04 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
US6632443B2 (en) 2000-02-23 2003-10-14 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
US20080070981A1 (en) 2000-02-23 2008-03-20 Henryk Borowy-Borowski Water-soluble compositions of bioactive lipophilic compounds
AR025587A1 (en) 1999-09-13 2002-12-04 Hoffmann La Roche DISPERSION FORMULATIONS CONTAINING LIPASA INHIBITORS
EP1246668B1 (en) * 1999-12-01 2005-11-30 Natco Pharma Limited An rapid acting freeze dired oral pharmaceutical composition for treating migraine
WO2001052826A2 (en) * 2000-01-20 2001-07-26 Supratek Pharma Inc. Novel podophyllotoxin compositions
DE10046541A1 (en) * 2000-09-19 2002-03-28 Knoll Ag Oral dosage form useful as nutritional supplement or medicament comprises solid dispersion of ubiquinone in thermoplastic matrix
AR033711A1 (en) * 2001-05-09 2004-01-07 Novartis Ag PHARMACEUTICAL COMPOSITIONS
MXPA04003625A (en) 2001-10-19 2004-12-02 Sotechnika Inc CYCLOSPORINE ANALOG SYNTHESIS.
FR2840614B1 (en) * 2002-06-07 2004-08-27 Flamel Tech Sa POLYAMINOACIDS FUNCTIONALIZED BY ALPHA-TOCOPHEROL AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS
WO2004050068A1 (en) 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
US7423004B2 (en) 2003-01-31 2008-09-09 Smithkline Beecham Corporation Solid dispersion compositions
WO2004073687A1 (en) * 2003-02-19 2004-09-02 H. Lundbeck A/S Method for preparation of an agglomerate using melt agglomeration
US20050096365A1 (en) * 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
US20070149509A1 (en) * 2003-12-18 2007-06-28 Luca Barella Use of vitamin e
WO2006036614A2 (en) * 2004-09-24 2006-04-06 Boehringer Ingelheim Pharmaceuticals, Inc. A new class of surfactant-like materials comprising vitamin e tpgs and a water soluble polymer
EP1793806A2 (en) * 2004-09-30 2007-06-13 Eastman Chemical Company Pharmaceutical formulations containing vitamin e tpgs molecules that solubilize lipophilic drugs without significant efflux inhibition, and use of such formulations
US20060088591A1 (en) * 2004-10-22 2006-04-27 Jinghua Yuan Tablets from a poorly compressible substance
US7446096B2 (en) * 2005-12-19 2008-11-04 Industrial Technology Research Institute Glutathione based delivery system
US8067380B2 (en) 2005-12-19 2011-11-29 Industrial Technology Research Institute Glutathione-based delivery system
WO2008007728A1 (en) * 2006-07-13 2008-01-17 Kaneka Corporation Oral preparation in the form enclosed in lipid membrane structure, and fatigue-ameliorating agent comprising coenzyme a as active ingredient
PE20081506A1 (en) 2006-12-12 2008-12-09 Infinity Discovery Inc ANSAMYCIN FORMULATIONS
CN102083467B (en) 2008-03-11 2013-12-25 Aska制药株式会社 Solid dispersion and its pharmaceutical composition, and their preparation method
BRPI0909185A2 (en) 2008-03-20 2015-08-25 Virun Inc Vitamin E derivative and its uses
PL2268160T3 (en) 2008-03-20 2013-05-31 Virun Inc Emulsions including a peg-derivative of tocopherol
AR075180A1 (en) * 2009-01-29 2011-03-16 Novartis Ag SOLID ORAL FORMULATIONS OF A PYRIDOID-PYRIMIDINONE
JPWO2010092925A1 (en) * 2009-02-12 2012-08-16 あすか製薬株式会社 Solid dispersion, pharmaceutical composition thereof, and production method thereof
US8252821B2 (en) * 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
CA2792330C (en) 2010-03-23 2017-01-03 Virun, Inc Nanoemulsion including a peg-derivative of vitamin e and a sucrose fatty acid ester
WO2011162802A1 (en) 2010-06-21 2011-12-29 Virun, Inc. Compositions containing non-polar compounds
ITMI20112042A1 (en) * 2011-11-10 2013-05-11 Eratech S R L POWDER TO RECONSTITUTE BEFORE INCLUDING MELATONIN AND INJECTABLE PREPARATION OBTAINABLE FROM SUCH POWDER.
ITRM20120331A1 (en) 2012-07-12 2014-01-13 Guidotti & C Spa Labor LIQUID ORAL PEDIATRIC COMPOSITIONS CONTAINING NEPADUTANT.
FR2999081B1 (en) * 2012-12-06 2015-02-27 Hra Pharma Lab SOLID DISPERSION OF A SELECTIVE PROGESTERONE RECEPTOR MODULATOR
US9351517B2 (en) 2013-03-15 2016-05-31 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and compositions containing same
US9693574B2 (en) 2013-08-08 2017-07-04 Virun, Inc. Compositions containing water-soluble derivatives of vitamin E mixtures and modified food starch
HUP1300647A2 (en) * 2013-11-12 2015-05-28 Druggability Technologies Ip Holdco Jersey Ltd Complexes of cyclosporine a and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
US11911361B2 (en) 2014-05-29 2024-02-27 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
US11331279B2 (en) 2014-05-29 2022-05-17 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
US12544389B2 (en) 2014-05-29 2026-02-10 Fresh Cut Development, Llc Stable cannabinoid formulations
GB201410869D0 (en) * 2014-06-18 2014-07-30 Perioc Ltd Novel pharmaceutical formulations and their use in the treatment of periodontal disease
US9861611B2 (en) 2014-09-18 2018-01-09 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and soft gel compositions, concentrates and powders containing same
US10016363B2 (en) 2014-09-18 2018-07-10 Virun, Inc. Pre-spray emulsions and powders containing non-polar compounds
CA2986268C (en) * 2015-05-28 2024-01-02 Insys Development Company, Inc. Stable cannabinoid formulations
EA201892396A1 (en) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. QUICKLY PRODUCTIVE PLANT MEDICINES AND BIOLOGICALLY ACTIVE ADDITIVES
US20190336472A1 (en) * 2017-01-03 2019-11-07 Receptor Holdings, Inc. Medicinal compounds and nutritional supplements
EP3582755A4 (en) * 2017-02-15 2020-12-23 Molecular Infusions, LLC FORMULATIONS
CN108245683B (en) * 2018-01-26 2020-02-14 华中科技大学 Anti-tumor prodrug with P-glycoprotein inhibition function and preparation method thereof
EP3883595A4 (en) 2018-11-19 2022-12-14 Receptor Holdings, Inc. N-ACYLATED N-FATTY AMINO ACIDS FOR REDUCING ABSORPTION VARIABILITY IN CANNABINOID COMPOSITIONS
EP4076405A1 (en) * 2019-12-20 2022-10-26 Idorsia Pharmaceuticals Ltd Pharmaceutical compositions comprising n-[1-(5-cyano-pyridin-2-ylmethyl)-1h-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide
KR20220119024A (en) * 2019-12-20 2022-08-26 인터벳 인터내셔널 비.브이. Pyrazole Pharmaceutical Compositions
CN115867285A (en) * 2020-03-19 2023-03-28 Ac免疫有限公司 Dosage therapy for tauopathies
IT202200002528A1 (en) * 2022-02-11 2023-08-11 Pierpaoli Exelyas S R L Composition including highly bioavailable melatonin

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996036316A1 (en) * 1995-05-19 1996-11-21 Abbott Laboratories Self-emulsifying formulations of lipophilic drugs
US5583105A (en) * 1994-11-21 1996-12-10 Biogal Gyogyszerguar Rt Oral pharmaceutical preparation
WO1997035587A1 (en) * 1996-03-22 1997-10-02 Glaxo Group Limited Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3102078A (en) * 1961-01-13 1963-08-27 Eastman Kodak Co Water-dispersible vitamin preparations
US3673163A (en) * 1970-06-16 1972-06-27 Lilly Co Eli Pharmacological preparation containing an acronycine-polyvinylprrolidone coprecipitate
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
US4327080A (en) * 1981-07-13 1982-04-27 E. R. Squibb & Sons, Inc. Novel Bendroflumethiazide formulations and method
US4758427A (en) * 1985-08-08 1988-07-19 Ciba-Geigy Corporation Enhanced absorption of psychoactive 2-aryl-pyrazolo quinolines as a solid molecular dispersion in polyvinylpyrrolidone
US5179122A (en) * 1991-02-11 1993-01-12 Eastman Kodak Company Nutritional supplement containing vitamin e
US5234696A (en) * 1991-12-27 1993-08-10 Abbott Laboratories Method of producing tablets, tablets produced thereby, and method of treatment using same
IT1255792B (en) * 1992-08-05 1995-11-16 Bayer Italia Spa PHARMACEUTICAL COMPOSITIONS FOR THE ORAL ADMINISTRATION OF DIHYDROPYRIDINS IN THE FORM OF DRINK
US5430021A (en) * 1994-03-18 1995-07-04 Pharmavene, Inc. Hydrophobic drug delivery systems

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583105A (en) * 1994-11-21 1996-12-10 Biogal Gyogyszerguar Rt Oral pharmaceutical preparation
WO1996036316A1 (en) * 1995-05-19 1996-11-21 Abbott Laboratories Self-emulsifying formulations of lipophilic drugs
WO1997035587A1 (en) * 1996-03-22 1997-10-02 Glaxo Group Limited Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9808490A1 *

Also Published As

Publication number Publication date
CA2264718A1 (en) 1998-03-05
EP1017366A1 (en) 2000-07-12
CA2264718C (en) 2006-05-30
AU730216B2 (en) 2001-03-01
WO1998008490A1 (en) 1998-03-05
JP2001523221A (en) 2001-11-20
AU4237397A (en) 1998-03-19

Similar Documents

Publication Publication Date Title
EP1017366A4 (en) Solid coprecipitates for enhanced bioavailability of lipophilic substances
GB9602080D0 (en) Pharmaceutical compounds
HUP0003292A3 (en) Self-emulsifying formulation for lipophilic compounds
HUP0002486A3 (en) Self-emulsifying formulation for lipophilic compounds
ZA987551B (en) Solid pharmaceutical dosage forms
GB9817073D0 (en) Phase separator
GB9700504D0 (en) Pharmaceutical compounds
GB9609976D0 (en) Pharmaceutical compounds
GB9716244D0 (en) Pharmaceutical compounds
EP1003495A4 (en) Pharmaceutical compounds
GB9715490D0 (en) Pharmaceutical preparation
GB2321833B (en) Phase detector
GB9601527D0 (en) Phase separation apparatus
ZA982073B (en) Pharmaceutical preparation
GB9717173D0 (en) Solid phase supports
IL126050A0 (en) Sustained-release pharmaceutical formulations containing mizolastin
AU1118299A (en) Pharmaceutical grade garlic
ZA979329B (en) Pharmaceutical compounds
ZA98300B (en) Pharmaceutical compounds
GB9626151D0 (en) Pharmaceutical compounds
IL119176A0 (en) Solid coprecipitates for enhanced oral bioavailability of lipophilic substances
GB9621365D0 (en) Pharmaceutical compounds
ZA971668B (en) Pharmaceutical compounds
GB9609299D0 (en) Pharmaceutical compounds
GB9613997D0 (en) Pharmaceutical compounds

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990331

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PHARMOS CORPORATION

A4 Supplementary search report drawn up and despatched

Effective date: 20060203

17Q First examination report despatched

Effective date: 20060818

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20081014